Justin Sullivan/Getty Images News Gilead Sciences ( NASDAQ: GILD ) has agreed to collaborate with Cartography Biosciences to develop new therapies for triple-negative breast cancer and adenocarcinoma, the most common form of non-small cell lung cancer. The arrangement calls for the use of Cartography's computational and genomics platforms -- ATLAS and SUMMIT -- to discover and validate novel tumor-selective target antigens and pairs of antigens. The platforms "integrate single-cell data from a comprehensive healthy reference and tumor atlas – applying target identification algorithms to identify single or pairs of targets that are most specific to the intended target cells and optimized for therapeutic programs," according to a news release.
Terms call for Gilead to make a $20M upfront payment. Privately held Cartography is eligible for milestone payments as well as tiered royalties on sales for Gilead programs developed from the partnership. More on Gilead Sciences Gilead Sciences: Disappointing Fundamentals And Sentiment, But Still Bullish Unloved Gilead Due For Reversal On Flight-To-Safety Money Flows Why Gilead Sciences' 4.
6% Yield Doesn't Make The Cut For Smart Investors Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo Gilead touts additional data on liver disease asset seladelpar ahead of PDUFA date.
